Optimizing malaria treatment for children with severe malnutrition and adults with HIV
Informing optimal dosing of the future antimalarial, artemether-lumefantrine plus amodiaquine, in key neglected target populations of children with severe acute malnutrition and adults living with HIV
This study is looking at the best way to give malaria medications to young children with severe malnutrition and adults with HIV, to make sure they get the right dose for effective treatment and prevention of malaria.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kamuzu University of Health Sciences NIH-funded |
| Lab location | 1 site (Blantyre, Malawi) |
| Project ID | NIH-10979190 on NIH RePORTER |
What this research studies
This research investigates how to best dose the antimalarial drugs artemether-lumefantrine and amodiaquine in young children suffering from severe acute malnutrition and adults living with HIV. The study will assess how these conditions affect the absorption and effectiveness of the medications, aiming to ensure that patients receive the right amount to effectively treat and prevent malaria. By conducting clinical trials, the research will gather important data on drug safety and pharmacokinetics in these vulnerable populations. The findings could lead to improved treatment protocols tailored to the needs of these specific groups.
Who could benefit from this research
Good fit: Ideal candidates for this research include young children under 11 years old with severe acute malnutrition and adults over 21 years old who are living with HIV and receiving dolutegravir-based antiretroviral therapy.
Not a fit: Patients who do not have severe acute malnutrition or are not living with HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective malaria treatments for children with severe malnutrition and adults living with HIV, potentially reducing malaria-related morbidity and mortality in these populations.
How similar studies have performed: Previous research has shown that optimizing drug dosing in vulnerable populations can lead to significant improvements in treatment outcomes, suggesting that this approach has the potential for success.
Where this research is happening
Blantyre, Malawi
- Kamuzu University of Health Sciences — Blantyre, Malawi (Active)
Researchers
- Principal investigator: Banda, Clifford George — Kamuzu University of Health Sciences
- Study coordinator: Banda, Clifford George
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.